BioNTech (BNTX) announced that the Supervisory Board has appointed Kylie Jimenez to the Management Board as Chief People Officer, CPO, effective March 1, 2026. The appointment is in line with BioNTech’s strategy to become a multi-product oncology company by 2030 and underscores the importance of its global, highly skilled workforce in achieving this objective. In the newly created Management Board role, Kylie Jimenez will be responsible for shaping and leading BioNTech’s people strategy and its execution in alignment with the Company’s priorities and business goals. She will focus on attracting, developing and retaining talents and strengthening an inclusive culture. She will be based in the Company’s headquarters in Mainz, Germany.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- BioNTech’s New Phase III Prostate Cancer Trial Adds Long-Term Upside Potential for BNTX
- Pfizer and BioNTech Move Closer to a Single-Shot Flu–COVID Vaccine: What Investors Should Watch
- Bristol-Myers Squibb and BioNTech Advance New Phase 3 Lung Cancer Trial With Pumitamig
- Bristol-Myers Squibb and BioNTech Advance New Lung Cancer Weapon Against Keytruda in Phase 3 Trial
- Moderna Stock (MRNA) Hits a New 52-Week High — Can the Rally Last Through 2026?